meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
PD-L1 < 1%
PD-L1 > 1%
RAS mutant
RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Dyspnoea TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
hepatitis (Autoimmune) AE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Colitis AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Dermatitis acneiform AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dysphonia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Guillain-Barré syndrome AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Increased ALT AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Intestinal perforation AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Rash maculopapular AE (grade 3-4)
Sepsis AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
mCRC - 2nd line (L2)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
versus regorafenib
atezolizumab alone vs. regorafenib
1
certainty unassessable
0%
atezolizumab plus cometinib vs. regorafenib
1
certainty unassessable
0%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open